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the treatment groups (mean probability 0-12, 96% CI Ο ΟΊ-
Ο-18). 3 of the cases of eclampsia in group 3 were in the 7 women
who received only anticonvulsant drugs. Abruption occurred
with a similar frequency in all groups.
The hypothesis on which our study was based makes the
assumption that lowering BP will reduce the occurrence of
eclampsia and that adding an anticonvulsant will confer no
extra benefit. No difference in progression to eclampsia was
found between the two supervised study groups, which lends
support to the hypothesis, although on the basis of the
frequency with which eclampsia occurred in the study, this
number of patients does not allow a definitive conclusion. It
was not the intention of the study to see whether an
anticonvulsant alone would be sufficient to prevent
Progression to eclampsia, but there was a disproportionately
high occurrence of eclampsia in the small number of women in
die Standard treatment group who received only an
anticonvulsant. 3 of diese 7 women had eclampsia. Given the
frequency of eclampsia among patients who received both
antihypertensive and anticonvulsant medication in the
Standard treatment group, the probability of there being 3 cases
of eclampsia in any group of 7 patients is less than 0 006. This
findmg provides further indirect support for our hypothesis
and indicates that antihypertensive medication, with or
without an anticonvulsant, is better than an anticonvulsant
alone in preventing the progression to eclampsia. Based on the.
frequency of eclampsia in the Standard treatment group (12%)
and in the study groups, where effective antihypertensive
treatment was given (5%), 240 patients would be required in
groups l and 2 to confirm that adding an anticonvulsant does
not further reduce the occurrence of eclampsia at α=0 05 and
ß=02.
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Activated protein C reslstance in venous
thrombosls
SIR—Although we were pleased to read Tuddenham's
commentary (Dec 18/25, p 1501) accompanying our paper on
poor response to activated protein C (APC) and venous
thrombosis, we feel that some of its phrasing might confuse the
reader who is not familiär with the problems of hereditary
thrombotic disease. Our research started seeking causes of
thrombophilia. Nevertheless, our present study was not a study
of patients with thrombophilia, but of consecutive patients
with a first, objectively confirmed episode of deep-vein
thrombosis. Patients with thrombophilia are a rare group,
consisting of pfcople with spontaneous recurrent, often familial,
thrombosis at young age, among whom the bürden of
APC-resistance indeed amounts to 50%, äs found by othersi·2
and mentioned in the commentary. Among our group of
consecutive and unselected patients with a first episode of
venous thrombosis, APC resistance was present in 21%. The
difference is obviously due to the nature of the patient
selection, but at the same time proves that APC resistance is not
another rarity, but the single most important cause of
thrombosis in average patients.
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Author's reply
SIR—As Koster and Rosendaal point out, the incidence of
demonstrable coagulation defect in patients with venous
thromboembolism depends strongly on case selection, a fact
that I did not sufficiently emphasise in my commentary. The
definition of thrombophilia varies from author to author but
usually includes thrombosis under the age of 45, recurrence,
and positive family history. The hkelihood of identifying a
defect increases with the stringency of the definition. The
remarkable finding of the three published series is the very high
incidence of APC resistance exceeding that of the previously
identifiable defects put together. The overall incidence of APC
resistance remains to be established in various other groups
(arterial thrombosis, post-operative thrombosis, large
Segments of the normal population, ethnic subsets, &c), but
meanwhile chnical pathologists and others will wish to add the
lest to their "thrombophilia screen" äs soon äs possible.
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Activated protein C resistance in deep-vein
thrombosis
SIR—Koster and colleagues (Dec 18/25, p 1503) found a high
prevalence (21%) of poor anticoagulant response to activated
protein C (APC) in a series of unselected patients with
deep-vein thrombosis (DVT) before the age of 70, and
recommended the investigation of all patients with venous
thrombosis for this abnormality.
We evaluated response to APC in patients with juvemle
DVT. Frozen plasma samples (with normal activated partial
thromboplastin time [APTT]), stored at -70°C, from 228
patients (males, age 12-45) with DVT before age 45, without
underlying predisposing diseases (malignancy, nephrotic
syndrome) were tested. Blood had been sampled at least 3
months after the single or last venous thromboembolic episode
and 3 weeks after withdrawal of antithrombotic treatment.
APC response was measured by APC resistance
(Chromogenix, Sweden), which in our case proved to have an
8% between-assay Variation coefficient (CV). The results were
expressed äs APC sensitivity ratio, obtained äs follows:
APTT( + APC)/APTT(-APC). Normal value for APC
sensitivity ratio, obtained from the results of 40 healthy
age-matched subjects, was greater than 1-99. In the patients
examined, the results were quite similar to those of Koster et al,
a poor response to APC being recorded in 49 of 228 samples
(21 5%). However, in only 12 of the 24 who attended for repeat
testing was the result confirmed. The remaining 12 showed
normal APC sensitivity ratios; in all but l the difference from
the first result was greater than the between-assay CV. Among
the 49 cases with poor response to APC detected in the stored
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